Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.
in the DELIVER trial, adults with heart failure (HF) with mildly reduced and preserved ejection fraction were randomly assigned 10 mg dapagliflozin (Farxiga, AstraZeneca) or placebo daily for a median of 2.3 years. In the overall analysis, participants receiving dapagliflozin had a lower risk for the primary outcome of worsening HF or CV death compared with placebo. In new data presented at the European Association for the Study of Diabetes annual meeting, researchers analyzed DELIVER trial findings by diabetes status, with participants divided into groups without diabetes, with prediabetes or with type 2 diabetes.
“We truly have, for the first time, the first foundational therapy in HF across the entire range of ejection fraction,” Mikhail Kosiborod, MD, FACC, FAHA, cardiologist at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, said during the presentation. “It’s the first class of agents we’ve ever been able to say this about. These agents reduce CV deaths and hospitalizations for HF across the range of ejection fractions. They improve symptoms, physical limitations and quality of life across the range of ejection fraction, all with a favorable safety profile.”
Read the full Healio article: DELIVER: Dapagliflozin Cuts Risk for Worsening HF in Adults With, Without Type 2 Diabetes